Lilly’s Drops Peglispro Insulin; Now It Can Focus On Copycat Lantus
This article was originally published in The Pink Sheet Daily
The company will cease development of the novel long-acting insulin for the treatment of diabetes after previously revealing safety concerns. Lilly will take a $55mn charge in the fourth quarter.
Register for our free email digests: